iBio, Inc. (IBIO) stock

IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30

$0.73−0.03 (-4.00%)

Close on Nov 13, 2026Market cap $47.05MP/E –Yield –

iBio ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2019 it was -$15.61M.

Period	Period end	Value	Change
FY2019	Jun 30, 2019	-$15.61M	–
FY2012	Jun 30, 2012	-$9.00M	–
FY2011	Jun 30, 2011	-$9.28M	–

Change is against the same quarter a year earlier.

Periods

Period	Period end	Value	Change
Q2 FY2019CQ4 2018	Dec 31, 2018	-$3.84M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IBIO.

Revenue growth115.0% · median -35.6%

Operating margin-3491.0% · median -3982.7%

Net margin-3244.2% · median -1731.7%

Advertisement
300 × 250

See a number that looks wrong?